Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Revance Therapeutics (RVNC) Misses Q2 EPS by 2c
August 5, 2021 4:51 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($1.07), $0.02 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $18 million versus the consensus estimate of $15.48 million.
Cash, cash equivalents and short-term investments as of June 30, 2021 were $336.3 million.
For earnings history and... More
